Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human ASP8374 with or without pembrolizumab in advanced solid tumors
jRCT2080224990Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2019
- Modality
- Vaccines & Immunotherapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of ASP8374 in Nonhematologic neoplasms (2 arms), sponsored by Astellas Pharma. Primary endpoint: Safety and tolerability of ASP8374 (monotherapy and in combination with pembrolizumab). Started Dec 2019; status: completed.
02
Drugs
ASP8374
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080224990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224990.